SciSparc Pursues FDA Orphan Drug Designation for SCI-110 in Tourette Syndrome
Tel Aviv, Israel, September 2, 2026 SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. is pursuing U.S....
Cannabinoid Therapy
Advertisement
SciSparc Subsidiary NeuroThera Launches Phase IIb Trial of SCI-110 for Tourette Syndrome
TEL AVIV, Israel, Aug. 5, 2026 SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. has initiated a...
Artelo Biosciences Advances ART12.11 Following CBD Research Review
Solana Beach, Calif., July 22, 2026 Artelo Biosciences announced the publication of a peer-reviewed review article in the British...
BRC Therapeutics Secures FDA IND Clearance for BRC-002 Therapy
MONTEREY, California, USA, April 28, 2026 BRC Therapeutics has announced that the U.S. Food and Drug Administration has cleared...
IGC Pharma Expands Phase 2 CALMA Alzheimer’s Trial
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
Advertisement
